Tags

Type your tag names separated by a space and hit enter

Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
Eur J Intern Med. 2008 May; 19(3):203-8.EJ

Abstract

BACKGROUND

Mixed hyperlipidemia is a common disorder characterized by elevated VLDL and LDL levels. Patients with this syndrome usually are in need of combination therapy, comprising a fibric acid derivate with a statin drug in order to achieve LDL and triglyceride target values. Atorvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor demonstrated to be effective in reducing both cholesterol (CHOL) and triglyceride (TG) levels in humans. We examined the efficacy of atorvastatin as monotherapy in achieving a better or the same lipid profile in patients with mixed hyperlipidemia treated with combination therapy.

DESIGN

We compared atorvastatin with a combination of a fibric acid derivate and a statin drug (other than atorvastatin) in a 24-week, prospective randomized, open-label study of 27 patients with mixed hyperlipidemia.

METHODS

All 27 patients had been treated with statin-fibrate therapy in different regimens for at least a year. Atorvastatin at a daily dose of 20 mg was substituted for statin-fibrate therapy. Lipid and safety profiles were assessed.

RESULTS

Atorvastatin significantly reduced total cholesterol, LDL-C, and HDL-C compared to statin-fibrate therapy. In contrast, TG and glucose levels were significantly elevated with atorvastatin. Target LDL-C and TG was achieved in 10 patients with the single therapy of atorvastatin vs. 6 patients under statin-fibrate. In 16 patients, atorvastatin was at least as effective as, or better than, the combination therapy, and was recommended for continuation of treatment.

CONCLUSION

Atorvastatin is an adequate monotherapy for many mixed hyperlipidemia patients. We recommend atorvastatin be considered for every patient suffering from mixed hyperlipidemia.

Authors+Show Affiliations

Bnai Zion Medical Center, Rambam Medical Center and the Technion Faculty of Medicine, Haifa, Israel.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18395165

Citation

Avisar, Inbal, et al. "Atorvastatin Monotherapy Vs. Combination Therapy in the Management of Patients With Combined Hyperlipidemia." European Journal of Internal Medicine, vol. 19, no. 3, 2008, pp. 203-8.
Avisar I, Brook JG, Wolfovitz E. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia. Eur J Intern Med. 2008;19(3):203-8.
Avisar, I., Brook, J. G., & Wolfovitz, E. (2008). Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia. European Journal of Internal Medicine, 19(3), 203-8. https://doi.org/10.1016/j.ejim.2007.09.004
Avisar I, Brook JG, Wolfovitz E. Atorvastatin Monotherapy Vs. Combination Therapy in the Management of Patients With Combined Hyperlipidemia. Eur J Intern Med. 2008;19(3):203-8. PubMed PMID: 18395165.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia. AU - Avisar,Inbal, AU - Brook,J Gerald, AU - Wolfovitz,Efrat, Y1 - 2007/10/31/ PY - 2007/03/20/received PY - 2007/07/04/revised PY - 2007/09/27/accepted PY - 2008/4/9/pubmed PY - 2008/6/5/medline PY - 2008/4/9/entrez SP - 203 EP - 8 JF - European journal of internal medicine JO - Eur J Intern Med VL - 19 IS - 3 N2 - BACKGROUND: Mixed hyperlipidemia is a common disorder characterized by elevated VLDL and LDL levels. Patients with this syndrome usually are in need of combination therapy, comprising a fibric acid derivate with a statin drug in order to achieve LDL and triglyceride target values. Atorvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor demonstrated to be effective in reducing both cholesterol (CHOL) and triglyceride (TG) levels in humans. We examined the efficacy of atorvastatin as monotherapy in achieving a better or the same lipid profile in patients with mixed hyperlipidemia treated with combination therapy. DESIGN: We compared atorvastatin with a combination of a fibric acid derivate and a statin drug (other than atorvastatin) in a 24-week, prospective randomized, open-label study of 27 patients with mixed hyperlipidemia. METHODS: All 27 patients had been treated with statin-fibrate therapy in different regimens for at least a year. Atorvastatin at a daily dose of 20 mg was substituted for statin-fibrate therapy. Lipid and safety profiles were assessed. RESULTS: Atorvastatin significantly reduced total cholesterol, LDL-C, and HDL-C compared to statin-fibrate therapy. In contrast, TG and glucose levels were significantly elevated with atorvastatin. Target LDL-C and TG was achieved in 10 patients with the single therapy of atorvastatin vs. 6 patients under statin-fibrate. In 16 patients, atorvastatin was at least as effective as, or better than, the combination therapy, and was recommended for continuation of treatment. CONCLUSION: Atorvastatin is an adequate monotherapy for many mixed hyperlipidemia patients. We recommend atorvastatin be considered for every patient suffering from mixed hyperlipidemia. SN - 1879-0828 UR - https://www.unboundmedicine.com/medline/citation/18395165/Atorvastatin_monotherapy_vs__combination_therapy_in_the_management_of_patients_with_combined_hyperlipidemia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0953-6205(07)00263-4 DB - PRIME DP - Unbound Medicine ER -